Research on New Regimens for Retreatment Pulmonary Tuberculosis

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Multi-center, prospective study is performed to investigate the efficacy of new short-course regimen for retreatment pulmonary tuberculosis patients.

To obtain optimized short-course regimen, decrease treatment cost and improve success rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Collaborators: Centers for Disease Control and Prevention; Jiangsu Province Centers for Disease Control and Prevention; Shanghai Center for Disease Control and Prevention; Zhejiang University
• Treatments: Ethambutol; Isoniazid; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Pyrazinamide; Rifabutin; Rifampin; Streptomycin

Criteria

Inclusion Criteria:

• Sputum confirmed diagnosis of retreatment pulmonary tuberculosis

• Must be able to swallow tablets

• Must be able to sign written informed consent form

Exclusion Criteria:

• Extra-pulmonary tuberculosis

• Diabetes

• Allergy to any of the medications in the regimen or pregnancy

• Liver disease

• Renal disease

• Metabolic disease

• Immune system disease

• Hematological disease

• Nervous system and mental disease

• Endocrine disease

• Malignant disease

• Receiving immunosuppressive therapy

• HIV/AIDS

• Alcohol addiction